Aha-2024-desktop
Aha-2024-mobile

Transthyretin Amyloidosis (ATTR)

American Heart Association (AHA) 2024

Congress Details

calanderNovember 16-18, 2024

locationChicago, IL, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Image
Oral

Congress Materials

Image
icon Presentation Type
Presentation
Image
location icon Location
Chicago, IL, USA
Image
icon Title
A Phase 1, Single Ascending Dose Study to Evaluate ALN-TTRsc04, a Next-Generation RNA Interference Therapeutic, in Healthy Participants for Potential Treatment of Transthyretin Amyloidosis
Image
icon Presentation Type
Presentation
Image
location icon Location
Chicago, IL, USA
Image
icon Title
Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial